IMMUNOSCAPE, a biotech startup specialising in cancer treatment, has raised US$14 million to scale up its operations in Singapore and the US, as well as to improve its immune profiling technology. This brings the startup’s total funding in the past year to S$25 million. Read more at The Business Times.